|
|
|
|
|
|
|
|
Objective
Serial circulating tumor cell (CTC) counts have demonstrated predictive and prognostic value in patients with metastatic breast, colorectal, and prostate cancer.
In a phase III study of pegylated liposomal doxorubicin (PLD) with trabectedin vs. PLD for relapsed ovarian cancer, we evaluated the correlation, if any, between numbers of CTCs and progression free survival, (PFS) and overall survival (OS).
Conclusions
Results from this study indicate that elevated numbers of CTCs impart an unfavorable prognosis for ovarian cancer patients.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.